rethinkPeptides Search
Menu
Study breakdown

Large Meta-Analysis of 97,000 Patients Finds GLP-1 Drugs Before Surgery Don't Increase Complications

evidence
The takeaway

Preoperative GLP-1 receptor agonist use showed no signal of increased surgical complications across 97,059 patients in 21 studies, while achieving meaningful pre-surgery weight loss of up to 16.7 kg.

No increased surgical risk (OR 0.78)

Across 97,059 patients in 21 studies, preoperative GLP-1RA use showed a non-significant trend toward fewer — not more — perioperative complications

What the researchers found

Among 97,059 patients across 21 studies (30,981 received preoperative GLP-1RA), postoperative complications showed no increased risk in GLP-1 users (pooled OR: 0.78, 95% CI: 0.59-1.05). Bayesian meta-analysis confirmed this (posterior mean OR: 0.78, 95% credible interval: 0.57-1.12). Meta-regression found no significant effect modifiers. Preoperative weight loss of up to 16.7 kg or 6.0 kg/m² was reported over six months. Overall GRADE certainty of evidence was very low due to observational designs and high heterogeneity (I²=73%).

Why it matters

Anesthesiologists have raised concerns about GLP-1 drugs delaying gastric emptying, potentially increasing aspiration risk during surgery. Some guidelines have recommended holding these drugs before elective procedures. This comprehensive meta-analysis — the largest to date — provides evidence that preoperative GLP-1RA use does not increase overall surgical complications, which could change perioperative management guidelines and support continued or initiated GLP-1RA use for surgical optimization.

How the study worked

Systematic review and meta-analysis (PROSPERO registered) searching PubMed, MEDLINE, Embase, and Cochrane Library through March 2025. 21 studies meeting inclusion criteria were analyzed using both frequentist and Bayesian random-effects meta-analyses. Primary outcome was 90-day perioperative complications; secondary outcome was preoperative weight loss. GRADE assessment evaluated evidence certainty. Bayesian hierarchical meta-regression explored effect modifiers.

What this study cannot tell us

All 21 studies were observational — no randomized trials exist. The GRADE certainty was very low. High heterogeneity (I²=73%) suggests substantial variability across studies that meta-regression could not explain. Most studies were single-center from high-income countries, limiting generalizability. The specific concern about aspiration risk during anesthesia was not separately assessed. Publication bias cannot be excluded. The pooled OR of 0.78 did not reach statistical significance.

How to read the evidence

The authors' own GRADE assessment rated the evidence as very low certainty. While the pooled sample size is large (97,059), all contributing studies were observational with risk of bias, and heterogeneity was substantial. The absence of any randomized trials is a critical limitation.

When this study was published

Published in 2025 in EClinicalMedicine (Lancet group), this meta-analysis is the most comprehensive assessment of perioperative GLP-1RA safety to date, directly addressing a current clinical controversy.

The bigger picture

With obesity reaching epidemic proportions and surgical waitlists growing globally, the potential to use GLP-1 drugs for preoperative optimization is enormous. If these drugs can safely reduce weight before surgery — potentially lowering surgical complications, improving recovery, and enabling patients previously deemed too high-risk for procedures — the impact on healthcare systems could be transformative. This meta-analysis provides the best available evidence supporting this approach, while correctly highlighting the urgent need for randomized trials.

Questions still open

  • Should current guidelines recommending GLP-1RA cessation before surgery be revised based on this evidence?
  • Is the non-significant trend toward fewer complications (OR 0.78) a real protective effect of preoperative weight loss?
  • Do specific surgical types (bariatric, orthopedic, cardiac) show different safety profiles with preoperative GLP-1RA use?

Common questions

Should I stop taking Ozempic before surgery?
Current guidelines vary — some recommend stopping GLP-1 drugs 1-3 weeks before surgery due to concerns about delayed stomach emptying and aspiration risk during anesthesia. This meta-analysis of 97,000 patients found no evidence of increased surgical complications, but the evidence quality is very low. The safest approach is to discuss timing with your surgeon and anesthesiologist, who can make individualized recommendations.
Could GLP-1 drugs help patients prepare for surgery?
The evidence suggests yes — preoperative GLP-1 drug use achieved meaningful weight loss (up to 16.7 kg over 6 months) without increasing surgical complications. For obese patients needing elective surgery, losing weight beforehand can improve surgical outcomes. If future randomized trials confirm these findings, preoperative GLP-1 therapy could become a standard part of surgical preparation for obese patients.

Read the original research

Evaluation of safety of preoperative GLP-1 receptor agonists in patients undergoing elective surgery: a systematic review, meta-analysis and meta-regression.

EClinicalMedicine, 87, 103408

Citation

Kamarajah, Sivesh K; Gudiozzi, Nadia; Findlay, John M; Lee, Matthew J; Pinkney, Thomas; Markar, Sheraz R. (2025). Evaluation of safety of preoperative GLP-1 receptor agonists in patients undergoing elective surgery: a systematic review, meta-analysis and meta-regression.. EClinicalMedicine, 87, 103408. https://doi.org/10.1016/j.eclinm.2025.103408